# MDT-BRIDGE (NCT05925530)

> Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05925530
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: AstraZeneca
- Conditions: Non-small Cell Lung Cancer
- Interventions: Durvalumab
- Enrollment: 142
- Primary outcome: Resection rate

## Commentary we found

- X threads: 67
- YouTube: 12
- Podcasts: 8
- X videos: 1

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=mdt-bridge-nct05925530

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05925530", "email": "<work email>"}; the inbox owner confirms by the emailed link.